{"id":7400,"date":"2022-11-15T09:16:01","date_gmt":"2022-11-15T09:16:01","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=7400"},"modified":"2022-12-14T10:37:01","modified_gmt":"2022-12-14T10:37:01","slug":"xavier-mariette-acr-2022-malignancy-rates-with-filgotinib-in-rheumatoid-arthritis-and-ulcerative-colitis","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/rheumatology\/conference-hub\/xavier-mariette-acr-2022-malignancy-rates-with-filgotinib-in-rheumatoid-arthritis-and-ulcerative-colitis\/","title":{"rendered":"Xavier Mariette, ACR 2022: Malignancy rates with filgotinib in rheumatoid arthritis and ulcerative colitis"},"content":{"rendered":"

Data from the ORAL Surveillance study (NCT02092467<\/a>) suggested that malignancy risk is higher in people with active RA aged \u226550 years when using the JAK 1 inhibitor filgotinib vs TNF inhibitors. In this touchIMMUNOLOGY interview we spoke with Prof. Xavier Mariette<\/strong> (Paris-Saclay University, Ile-de-France, France) around his study investigating the malignancy incidence and event rates in clinical trials of filgotinib for the treatment of rheumatoid arthritis and ulcerative colitis.<\/p>\n

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.<\/b><\/p>\n

The abstract ‘Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs<\/em><\/a>.’ (Abstract number: 0277) was presented at the ACR Convergence<\/a>, November 10\u201314, 2022.<\/span><\/p>\n

Questions<\/b><\/p>\n

    \n
  1. What is known about the malignancy risk of janus kinase (JAK) 1 inhibitors in the treatment of rheumatoid arthritis (RA) and ulcerative colitis (UC)? (0:11)<\/span><\/li>\n
  2. What were the aims and design of your study? (0:48)<\/span><\/li>\n
  3. What was the incidence of malignancy events and what risk factors were identified? (2:19)<\/span><\/li>\n
  4. What was the impact of filgotinib on malignancies in UC and RA? (3:34)\u00a0<\/span><\/li>\n
  5. What are the key take home messages of this study? (4:33)<\/span><\/li>\n<\/ol>\n

    Disclosures:<\/b> Xavier Mariette discloses receiving honoraria from Astra-Zeneca, BMS, Galapagos, GSK, Novartis, and Pfizer.<\/span><\/p>\n

    Support:<\/b> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/span><\/p>\n

    Filmed in coverage of the ACR Convergence 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    Data from the ORAL Surveillance study (NCT02092467) suggested that malignancy risk is higher in people with active RA aged \u226550 years when using the JAK 1 inhibitor filgotinib vs TNF inhibitors. In this touchIMMUNOLOGY interview we spoke with Prof. Xavier Mariette (Paris-Saclay University, Ile-de-France, France) around his study investigating the malignancy incidence and event rates […]<\/p>\n","protected":false},"featured_media":7411,"template":"","class_list":["post-7400","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-rheumatology","video_categories-acr-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":8,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7400\/revisions"}],"predecessor-version":[{"id":8234,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/7400\/revisions\/8234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/7411"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=7400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}